©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113816
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113816
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113816
Figure 2 Risk of bias assessment for randomized controlled trials using the Cochrane RoB 2.
0 tool. The figure presents the domain-specific and overall risk of bias judgments for the two included randomized controlled trials. One trial exhibited high risk in allocation concealment, while both demonstrated low risk in other domains such as blinding, outcome measurement, and attrition.
- Citation: Cheng Z, Yue AM. Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastrointest Oncol 2026; 18(1): 113816
- URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113816.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113816